Phase III study of hpatinib in the treatment of advanced gastric cancer

According to Hengrui pharmaceutical company, apatinib's phase III research on the treatment of advanced gastric cancer will make an oral report at the annual meeting of the American Society of Clinical Oncology (ASCO) and be selected as an excellent paper, which is the first time among domestic enterprises ASCO annual meeting is an academic event in the field of cancer treatment, which will be held in Chicago from May 30 to June 3 local time It is expected to attract more than 25000 tumor professionals from all over the world According to the above company, Professor Li Jin from Fudan University Cancer Hospital was the speaker who made the oral report of apatinib at the ASCO annual meeting, and he was also one of the main leaders of apatinib research project Apatinib is the first molecular targeted drug for advanced gastric cancer in the world, and it is also the first kind of Hengrui medicine that is expected to be listed in the research and development of new drugs In addition to the indications of gastric cancer declared for production, the company is also carrying out clinical trials for indications of liver cancer According to the Research Report of GF Securities, the market space of apatinib for gastric cancer and liver cancer indications is expected to reach 1 billion yuan According to CFDA website, apatinib has completed the pharmacotoxicology, clinical and pharmaceutical evaluation project of CDE and will enter the site for inspection According to the new drug review process, apatinib is expected to be approved for marketing within this year if it goes well